CVS Health Q2 2026 earnings beat, Eli Lilly weight loss drug deal

CVS Health announced a collaboration with Eli Lilly connected Wednesday arsenic the institution reported second-quarter nett income of astir $3 cardinal and raised its full-year outlook by a wide margin.

Net income for the 4th ended June 30 came successful astatine $2.98 billion, oregon $2.31 per share, a crisp betterment from $1.02 billion, oregon 80 cents per share, successful the year-ago quarter. Adjusted net came to $2.58 per share. Analysts had expected adjusted net of $1.85 per share, according to CNBC.

Revenue roseate to $106.10 billion, up astir 7% from the year-ago period. Analysts had expected $100.11 billion, according to CNBC.

CVS besides lifted its full-year adjusted net guidance to betwixt $7.90 and $8.10 per share, up from its erstwhile scope of $7.30 to $7.50 per share. Full-year gross guidance roseate to astatine slightest $414 cardinal from astatine slightest $405 billion, the institution said.

All 3 concern segments topped Wall Street gross expectations. The wellness services division, which is anchored by pharmacy payment manager Caremark, brought successful $51.8 cardinal successful revenue, an 11.5% summation implicit the aforesaid play past year. The security segment, which houses Aetna, recorded $37.54 cardinal successful revenue, astir 3.5% up of the prior-year quarter. The pharmacy and user wellness part tallied $33.82 cardinal successful sales, edging up astir 0.7% twelvemonth implicit year.

Aetna's aesculapian payment ratio, which tracks what the insurer pays retired successful aesculapian claims against the premiums it takes in, improved to 87.4% from 89.9% successful the prior-year period, the institution said. When the ratio declines, it signals that premium gross exceeded payment payouts by a wider margin. Analysts had expected a ratio of 89.8%.

Under its concern with Eli Lilly, CVS said the CVS Health app volition show pricing accusation for Zepbound and Foundayo — 2 of Lilly's GLP-1 therapies — for eligible patients starting successful aboriginal 4th fourth 2026, with the enactment for same-day pickup astatine CVS pharmacy locations. CVS said it already carries oral and injectable formulations of Wegovy, making it a destination for each FDA-approved value nonaccomplishment drugs successful the class.

As portion of the broader value absorption programme revamp, CVS chopped the terms of MinuteClinic virtual value nonaccomplishment consultations to $29, dropping immoderate rank oregon recurring interest requirement, the institution said. Eligible patients link with a licensed clinician who tin measure and, wherever appropriate, prescribe value nonaccomplishment cause therapy, with same-day medicine pickup disposable astatine astir 9,000 CVS pharmacy locations.